SCI offers Innovation Awards to support collaborative projects focused on acceleration of basic, translational, clinical and population-based cancer research, and projects focused on cancer care, such as pancreatic, breast and gynecologic cancers.
Stanford University’s Innovative Medicines Accelerator (IMA) is accepting proposals for projects that use a recent advance in human organ modeling to address the IMA’s goals of accelerating the prototyping of innovative medicines and vaccines.
DUE: October 2nd The Neuroscience:Translate program supports translational research addressing unmet needs in any area of neuroscience. Resulting technologies & therapies are intended to lead to licensing exits to eventually reach the patient.
To support biomedical research in diabetes, the Stanford Diabetes Research Center (SDRC) invites applications for the 2023-24 Pilot and Feasibility (P&F) Program led by Drs. Anna Gloyn and Sun H Kim.
The goal of the Institute for Human-Centered Artificial Intelligence research program is to foster interdisciplinary AI research that aims to improve the human condition. We seek proposals for up to $75,000 that support new ambitious ideas.
The Stanford SPARK program supports the discovery and development of novel therapeutics and diagnostics that address unmet medical needs by offering funding, education and project-specific mentorship.
Grants up to $250k along with strategic and advisory support to accelerate the commercial delivery of Stanford-based innovations from across the University.
C-ShARP (Community for Shared Advanced Research Platforms) invites new PIs to apply for Vouchers to be used in Stanford Shared Facilities. Vouchers will enable new PIs to navigate the facilities and to engage the staff of shared facilities.
Sanofi is awarding $150,000 funding for 1 year for translational research that can contribute to their early-stage pipeline and ultimately benefit patients. Please fill in the Pre-Proposal Submission Word Template before May 26th, 2023.
The Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug leads and optimizing drug prototypes.